Red: Avoid combination

Label

Interaction expected – Do not coadminister

Color

Red

Icon

Close Octagon Outline

Displaying 201 - 300 of 332

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Efavirenz EE/NGM 457	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of ethinyl estradiol and norgestimate		0.035 mg ethinyl estradiol / 0.25 mg norgestimate x 14 days	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decreased 82%	Use alternative contraceptive method
Efavirenz EE/NGM 456	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of ethinyl estradiol and norgestimate		0.035 mg ethinyl estradiol / 0.25 mg norgestimate x 14 days	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Use alternative contraceptive method
Efavirenz EE/NGM 455	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of ethinyl estradiol and norgestimate		0.025 mg ethinyl estradiol / 0.25 mg norgestimate	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Use alternative contraceptive method
Efavirenz Pimavanserin 454	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Decreased pimavanserin levels				Avoid combination and use alternative agents
Efavirenz G/P 453	Red: Avoid combination	Do not coadminister: Reduced levels of Pibrenatasvir / Glecaprevir	decreased pibrenatasvir / glecaprevir effects				Contraindicated. Use alternative agents.
Efavirenz Lumateperone 452	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Decreased Lumateperon levels				Avoid combination and use alternative agents
Efavirenz LNG 451	Red: Avoid combination	Do not coadminister: Reduced levels of levonorgestrel	Decreased levonorgestrel effects		0.75 mg x 1	Levonorgestrel AUC decreased 64%; Cmax decreased 45%; Cmin decreased 71%; half-life: decreased 47%	Use alternative contraceptive method
Efavirenz G/P 450	Red: Avoid combination	Do not coadminister: Reduced levels of glecaprevir / pibrentasvir	Possible decrease in glecaprevir and pribrentasvir levels				contraindicated. Use alternative agents.
Efavirenz G/P 449	Red: Avoid combination	Do not coadminister: Reduced levels of glecaprevir / pibrentasvir	Possible decrease in glecaprevir and pribrentasvir levels				contraindicated. Use alternative agents.
Efavirenz ETR 448	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Decreased etravirine and efavirenz effects			Etravirine AUC decreased 41%	Use alternative agents
Efavirenz EBR/GZR 447	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir			Elbasvir 50 mg daily with grazoprevir 100 mg daily	Elbasvir AUC decreased 54% Grazoprevir AUC decreased 83%	Contraindicated. Use alternative agents.
Efavirenz EBR/GZR 446	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir	decreased of elbasvir / grazoprevir effects				Contraindicated. Use alternative agents.
Efavirenz EBR/GZR 445	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir	decreased of elbasvir / grazoprevir effects		Elbasvir 50 mg daily with grazoprevir 100 mg daily	Elbasvir AUC decreased 54% Grazoprevir AUC decreased 83%	Contraindicated. Use alternative agents.
Efavirenz Cariprazine 444	Red: Avoid combination	Do not coadminister: Reduced levels of cariprazine	Decreased cariprazine levels				Avoid combination and use alternative agents
Efavirenz CBZ 443	Red: Avoid combination	Do not coadminister: Reduced levels of carbamazepine and efavirenz	Decreased efavirenz and carbamazepine levels	Efavirenz AUC decreased 36%; Cmax decreased 21%; Cmin decreased 47%	200 mg daily on days 1-3, 200 mg BID on days 4-6, 400 mg daily thereafter	Carbamazepine AUC decreased 27%; Cmax decreased 20%; Cmin decreased 35%	Avoid combination and use alternative agents. If coadministering monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 442	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Potentially decreased or increased elvitegravir, cobicistat and / or efavirenz effects	Not studied (may decrease elvitegravir and cobicistat levels)		Not studied	Use alternative agents
Efavirenz St. John's Wort (Hypericum perforatum) 441	Red: Avoid combination	Do not coadminister: Potential for reduced levels of efavirenz	Decreased efavirenz effects	Not studied (may decrease efavirenz levels)		Not studied	Contraindicated. Use alternative agents.
Efavirenz ATV/c 440	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy	Not studied		Not studied (may decrease atazanavir and cobicistat levels)	Use alternative agents
Efavirenz ATV 439	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 43%, Cmax increased 17%	Use alternative agents
Efavirenz ATV 438	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 42%, Cmax increased 17%	Use alternative agents
Efavirenz ATV 437	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 48%.	Use alternative agents
Efavirenz ATV 436	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 14%.	Use alternative agents
Efavirenz ATV 435	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Use alternative agents
Efavirenz ATV 434	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Use alternative agents
Efavirenz Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 433	Red: Avoid combination	Do not coadminister: Potential for reduced antiviral activity	Significant GI and neurologic adverse events occurred, increase ALT	Not studied		Not studied (may decrease paritaprevir levels)	Contraindicated. Use alternative agents.
Efavirenz Ergotamine 432	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potentially increased ergotamine effects (eg, ergotism)	Not studied		Not studied (may increase ergotamine levels)	Avoid combination and use alternative agents
Doravirine EFV 359	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 62%; Cmax decreased 35%; C24 decreased 85%	600 mg x 1	Not studied	Do not coadminister. Use alternative agents.
Doravirine EFV 358	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 32%; Cmax decreased 14%; C24 decreased 50%	600 mg daily x 14 days	Not studied	Do not coadminister. Use alternative agents.
Doravirine RIF 357	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy.	AUC decreased 88%; Cmax decreased 57%, Cmin decreased 97%	600 mg daily	Not studied	Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.
Doravirine RFB 356	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Potential decrease in antiretroviral efficacy	AUC decreased 50%; Cmin decreased 68%	300 mg daily	Not studied	Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.
Doravirine NVP 355	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Do not coadminister. Use alternative agents.
Doravirine ETR 354	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Do not coadminister. Use alternative agents.
Doravirine St. John's Wort (Hypericum perforatum) 353	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing St. John's Wort, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Phenytoin 352	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing phenytoin, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Phenobarbital 351	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing phenobarbital, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Oxcarbazepine 350	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing oxcarbazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Mitotane 349	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing mitotane, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Enzalutamide 348	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing enzalutamide, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Doravirine Carbamazepine 347	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents. If discontinuing carbamazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Cabotegravir RIF 343	Red: Avoid combination	Do not coadminister: Reduced levels of CAB	Potential decrease in antiretroviral efficacy	Cmax decreased 6%, AUC decreased 59%, Cmin decreased 50%	600 mg once daily	Not studied	Contraindicated. Use alternative agents.
Cabotegravir Griseofulvin 342	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir St. John's Wort (Hypericum perforatum) 341	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir RPT 340	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Primidone 339	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Phenytoin 338	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Phenobarbital 337	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Oxcarbazepine 336	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Eslicarbazepine 335	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir Enzalutamide 334	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Cabotegravir CBZ 333	Red: Avoid combination	Do not coadminister: Potential for reduced levels of CAB	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Raltegravir Calcium carbonate 323	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 72%; Cmin decreased 48%	3000 mg single dose given with raltegravir	Not reported	Contraindicated. Use alternative agents.
Raltegravir Calcium carbonate 322	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 10%; Cmin decreased 57%	3000 mg single dose given 12 hours after raltegravir	Not reported	Contraindicated. Use alternative agents.
Raltegravir Aluminum and magnesium hydroxide antacid 321	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 49% if antacid given simultaneously. AUC decreased 51% if antacid given 2 hours before. AUC decreased 30% if antacid given 2 hours after. AUC decreased 19% if antacid given 4 hours before. AUC decreased 32% if antacid given 4 hours after. AUC decreased 11-13% if antacid given 6 hours before or 6 hours after.	20 mL single dose	Not reported	Contraindicated. Use alternative agents.
Raltegravir Aluminum and magnesium hydroxide antacid 320	Red: Avoid combination	Do not coadminister: Reduced levels of raltegravir		Raltegravir AUC decreased 14% if antacid given 12 horus after.	20 mL single dose	Not reported	Contraindicated. Use alternative agents.
Raltegravir Phenobarbital 319	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Raltegravir Eslicarbazepine 318	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Raltegravir CBZ 317	Red: Avoid combination	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Elvitegravir RPT 220	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Elvitegravir St. John's Wort (Hypericum perforatum) 219	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Eslicarbazepine 218	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Phenytoin 217	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Phenobarbital 216	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir RIF 215	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Expected significant decreased in elvitegravir, cobicistat. Potential decreased antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Clopidogrel 214	Red: Avoid combination	Do not coadminister: Potential for reduced levels of clopidogrel	Potential reduction of antiplatelet activity				Use alternative agents
Elvitegravir Vorapaxar 213	Red: Avoid combination	Do not coadminister: Potential for increased levels of vorapaxar	Potential for increased risk of bleeding				Avoid combination and use alternative antiplatelet agent
Elvitegravir Ticagrelor 212	Red: Avoid combination	Do not coadminister: Potential for increased levels of ticagrelor	Potential for increased risk of bleeding				Avoid combination and use alternative antiplatelet agent.
Elvitegravir Suvorexant 211	Red: Avoid combination	Do not coadminister: Potential for increased levels of suvorexant	Potential for increased suvorexant adverse effects				Use alternative agents
Elvitegravir Salmeterol 210	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	Increased risk of cardiovascular adverse events (e.g. QT prolongation, palpitations, sinus tachycardia)				Use alternative agents
Elvitegravir Ranolazine 209	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Potential for increased risk of ranolazine adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Ivabradine 208	Red: Avoid combination	Do not coadminister: Potential for increased levels of ivabradine	Potential for increased risk of ivabradine adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Flibanserin 207	Red: Avoid combination	Do not coadminister: Potential for increased levels of flibanserin	Potential for increased risk of flibanserin adverse effects				Use alternative agents
Elvitegravir Eplerenone 206	Red: Avoid combination	Do not coadminister: Potential for increased levels of eplerenone	Potential for increased risk of eplerenone adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Dofetilide 205	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Potential for increased risk of dofetilide adverse effects				Use alternative agents
Elvitegravir Lumateperone 204	Red: Avoid combination	Do not coadminister: potential toxicity	Potential for increased risk of lumateperone adverse effects				Use alternative agents
Elvitegravir Lurasidone 203	Red: Avoid combination	Do not coadminister: potential toxicity	Potential serious or life-threatening reactions				Contraindicated. Use alternative agents.
Elvitegravir Triazolam 202	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Potential for increased triazolam effects (e.g. prolonged sedation, altered mental status, respiratory depression)				Contraindicated. Use alternative agents.
Elvitegravir Triamcinolone 201	Red: Avoid combination	Do not coadminister: Potential for increased levels of triamcinolone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Do not coadminister if triamcinolone is used for local injection.
Elvitegravir Simvastatin 200	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Potential for increased simvastatin effects (e.g. myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Elvitegravir Simeprevir 199	Red: Avoid combination	Do not coadminister: Potential for increased levels of simeprevir	Potential for increased simeprevir toxicity				Use alternative agents
Elvitegravir Silodosin 198	Red: Avoid combination	Do not coadminister: Potential for increased levels of silodosin	Potential for increased silodosin adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Pimozide 197	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Potential serious or life-threatening reactions such as cardiac arrhythmia.				Contraindicated. Use alternative agents.
Elvitegravir Mometasone 196	Red: Avoid combination	Do not coadminister: Potential for increased levels of mometasone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Use alternative agents
Elvitegravir Midazolam 195	Red: Avoid combination	Do not coadminister: Potential for increased levels of midazolam	Potential for increased midazolam effects (e.g. prolonged sedation, altered mental status, respiratory depression)				Co-administration of oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation.
Elvitegravir Alprazolam 194	Red: Avoid combination	Do not coadminister: Potential for increased levels of midazolam	Potential for increased alprazolam effects (e.g. sedation, altered mental status, respiratory depression)				Coadministration of EVG with oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation.
Elvitegravir Methylprednisolone 193	Red: Avoid combination	Do not coadminister: Potential for increased levels of methylprednisolone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Do not coadminister if methylprednisolone being used for local injection.
Elvitegravir Methylergonovine 192	Red: Avoid combination	Do not coadminister: Potential for increased levels of methylergonovine	Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Elvitegravir HMG-CoA Reductase Inhibitors 191	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Potential for increased lovastatin effects (e.g. myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Elvitegravir Fluticasone 190	Red: Avoid combination	Do not coadminister: Potential for increased levels of fluticasone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Use alternative agents
Elvitegravir Ergotamine 189	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Elvitegravir Dihydroergotamine 188	Red: Avoid combination	Do not coadminister: Potential for increased levels of dihydroergotamine	Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Elvitegravir EBR/GZR 187	Red: Avoid combination	Do not coadminister: Potential for increased levels of antivirals	Potential for increased AUC of HCV agents	No significant change		Elbasvir Cmax increased 91%, AUC increased 118%; Grazoprevir Cmax increased 359%, AUC increased436%	Use alternative agents
Elvitegravir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 186	Red: Avoid combination	Do not coadminister: Potential for increased levels of antivirals	Potential for increased AUC of HCV agents				Use alternative agents
Elvitegravir Alfuzosin 185	Red: Avoid combination	Do not coadminister: Potential for increased levels of alfuzosin	Potential for increased alfuzosin adverse effects (e.g. hypotension)				Contraindicated. Use alternative agents.
Elvitegravir Lomitapide 184	Red: Avoid combination	Do not coadminister: Potential for increased level of lomitapide	Potential for increased risk of elevated transaminases				Contraindicated. Use alternative agents.
Elvitegravir Avanafil 183	Red: Avoid combination	Do not coadminister: Potential for increased level of avanafil	Potential for increased risk avanafil adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Dapagliflozin / Saxagliptin 182	Red: Avoid combination	Do not coadminister: Increased levels of saxagliptin	Potential for increased saxagliptin adverse effects	Not reported	saxagliptin 5 mg	Not reported	Use alternative agents
Elvitegravir CBZ 136	Red: Avoid combination	Do not coadminister: Reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 45%, AUC decreased 69%, Cmin decreased 97%	200 mg BID	Cmax increased 40%, AUC increased 43%, Cmin increased 51%. Epoxide metabolite (pharmacologically active) Cmax decreased 73%, AUC decreased 35%, and Cmin decreased 41%.	Contraindicated. Use alternative agents.
Elvitegravir RFB 135	Red: Avoid combination	Do not coadminister: Increased levels of rifabutin, reduced levels of elvitegravir	Increased rifabutin effects, potential loss of antiretroviral activity	Cmax decreased 9%, AUC decreased 21%, Cmin decreased 67%	150 mg every other day	No significant change in rifabutin Cmin, AUC, or Cmax. 25-O-desacetylrifabutin metabolite Cmax increased 384%, AUC increased 625%, Cmin increased 394% as compared to 300 mg rifabutin alone.	Use alternative agents
Dolutegravir CBZ 124	Red: Avoid combination	Do not coadminister: Reduced levels of dolutegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 33%, AUC decreased 49%, Cmin decreased 73%	300 mg BID	Not studied	Use alternative agents. If this combination must be used in an INSTI-na•ve adult patient, adminster dolutegravir 50 mg twice daily. Do not use in cases of clinically suspected InSTI resistance. Monitor antiviral efficacy
Dolutegravir ETR 123	Red: Avoid combination	Do not coadminister: Reduced levels of dolutegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 52%, AUC decreased 71%, Cmin decreased 88%	200 mg once daily	Not studied	Contraindicated. Use in combination with ATV / r or DRV / r

Subscribe to Red: Avoid combination